[{"orgOrder":0,"company":"Viwit Pharmaceuticals Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Bimatoprost","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Viwit Pharmaceuticals Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Viwit Pharmaceuticals Limited \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Viwit Pharmaceuticals Limited \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Viwit Pharmaceuticals Limited

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Medlab Asia & Asia Health
                          Not Confirmed
                          Medlab Asia & Asia Health
                          Not Confirmed

                          Details : Bimatoprost-Generic is the first prostaglandin analog that is preservative free for the reduction of elevated intraocular pressure in patients with open-angled glaucoma or ocular hypertension.

                          Brand Name : Bimatoprost-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 09, 2024

                          Lead Product(s) : Bimatoprost

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank